Form 4: Caris Life Sciences Director Acquires Shares as Compensation

A director at Caris Life Sciences, David Paul Fredrickson, acquired 2,492 shares of common stock as compensation for 2025 board retainer fees.

Summary

• David Paul Fredrickson, a Director of Caris Life Sciences, Inc. (CAI), acquired 2,492 shares of common stock.
• The transaction occurred on February 26, 2026, at a price of $20.06 per share.
• These shares were issued in lieu of cash compensation for 2025 board retainer fees.
• The number of shares was determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.
• Following this transaction, Fredrickson beneficially owns a total of 18,621 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While not an open market purchase, the director's receipt of shares as compensation increases their direct stake in the company, aligning their financial interests with long-term shareholder value.

Positives

• A director receiving shares as compensation aligns their interests with those of shareholders, demonstrating continued commitment to the company's performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity compensation for board members is a standard practice across various industries, including life sciences, to incentivize long-term value creation and align management interests with shareholder returns.

Comparison to Industry Standards

• Equity compensation for directors, such as the issuance of shares in lieu of cash, is a common practice in publicly traded companies across the biotechnology and life sciences sectors, aligning director incentives with company performance.
• The valuation method, using a volume-weighted average price, is a standard and transparent approach for determining the number of shares issued in such compensation arrangements.

Stakeholder Impact

• Shareholders: The transaction increases a director's equity stake, potentially signaling confidence and aligning interests with long-term shareholder value.

Key Dates

Keywords

Caris Life Sciences, CAI, Insider Transaction, Form 4, Director Compensation, Equity Compensation, Stock Acquisition